Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod

ClinicalTrials.gov Identifier: NCT02232061

Novartis Reference Number: CFTY720D2409

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events

Condition 
Multiple Sclerosis
Phase 
Phase 4
Overall status 
Recruiting
Enrollment count 
40 participants
Start date 
Sep 29, 2014
Completion date 
Jul 06, 2020
Gender 
All
Age(s)
(Child, Adult, Older Adult)

Interventions

Drug
Fingolimod

Eligibility Criteria

Inclusion Criteria:

Patients participating in study FTY720D2406 who experienced a serious cardiovascular event during their fingolimod treatment initiation
Patients still on fingolimod after the this first dose serious event

Exclusion Criteria:

-

Study Locations

Belgium
Novartis Investigative Site
Recruiting
Gent, 9000
-
Belgium
Novartis Investigative Site
Recruiting
Hasselt, 3500
-
Belgium
Novartis Investigative Site
Withdrawn
Verviers, 4800
-
Belgium
Germany
Novartis Investigative Site
Recruiting
Ravensburg, 88212
-
Germany
Novartis Investigative Site
Recruiting
Trier, 54292
-
Germany
Italy
Novartis Investigative Site
Recruiting
Napoli, 80131
-
Italy

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Name: 
Novartis Pharmaceuticals
Phone: 
Email: 

Have a question?

Call 1-999-669-6682 or email [email protected]